Trial Profile

A phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Dec 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Paclitaxel
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions

Most Recent Events

15 Dec 2015 New trial record
11 Dec 2015 Early data presented at the San Antonio Breast Cancer Symposium 2015, according to a Roche media release.
11 Dec 2015 Early data published in a Roche media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com